HK inno.N launches K-CAB ODT 25mg for treatment of GERD
June 27, 2024
HK inno.N launches K-CAB ODT 25mg for treatment of GERD
Designed to be rapidly dissolved in the mouth without the need for swallowing … To be released on the 1st of July
Releasing 25mg (low-dose) following the launch of the existing product, K-CAB ODT 50mg…
Development ongoing for ensuring availability in diverse formulations and doses
The only product with ODT formulation and indication for maintenance therapy among P-CAB class products released in Korea
HK inno.N announced on 27th that the low-dose form (25mg) of the company’s blockbuster drug K-CAB (tegoprazan) ODT for treatment of gastroesophageal reflux disease (GERD) will be launched as of 1st of July. As with K-CAB Tablet 25 mg, the new product is indicated for “maintenance therapy after treatment of erosive GERD.”
K-CAB is the only product available in the formulation of orally disintegrating tablet (ODT) among the P-CAB class products released in Korea. K-CAB ODT rapidly dissolves in the mouth, which provides a patient-friendly option for those having difficulty swallowing tablets or drinking water or patients of advanced age.
HK inno.N released K-CAB ODT 50mg in May 2022, and its half-dose formulation, K-CAB ODT 25mg will be released next month. Following the new product launch, the K-CAB product series is now available in four different types to meet diverse needs of the patients: ▲ K-CAB Tablet 25mg ▲ K-CAB Tablet 50mg ▲ K-CAB ODT 25mg ▲ K-CAB ODT 50mg.
The cumulative outpatient prescription sales of K-CAB series in the last year alone recorded KRW 158.2 billion, continuing to cement its position as the No. 1 market leader in peptic ulcer drugs in Korea. Among the products, K-CAB ODT 50mg, released in 2022, recorded the outpatient prescription sales at KRW 25.1 billion for the last year, making its mark in the ongoing trend of rapid growth of K-CAB series. It is expected that the launch of the new low-dose ODT product will further contribute to the sales growth and market share expansion of K-CAB series.
An official from HK inno.N commented, “Through continuous R&D, the available formulations and dose options of K-CAB have diversified, as well as expanding its indications, which contributes to boosting patient compliance and providing a wider range of therapeutic options for the patients,” and added, “Our multifaceted efforts will continue to solidify K-CAB series’ market leading position for peptic ulcer drugs in Korea, and provide added values to new drugs manufactured in Korea.
K-CAB, the 30th new drug in South Korea, provides a next-generation option for treatment of GERD, overcoming limitations of the existing therapeutic agents. Since its release in 2019, K-CAB has been the steady No. 1 market leader in peptic ulcer medications for four consecutive years. The drug’s cumulative outpatient prescription sales up to May 2024 has reached KRW 585.3 billion. K-CAB is approved for five indications, boasting the most diverse range of indications among P-CAB class products released in Korea. It is characterized by rapid onset of action within one hour after administration, suppression of night-time gastric acid secretion, and boosting patient compliance with its simplified regimen irrespective of meal times. The diverse dose and formulation options of K-CAB allows the drug to be used across a range of stages from treatment of GERD to maintenance therapy. [The end]
[Reference Information]
■ P-CAB: Potassium Competitive Acid Blocker
■ Indications of K-CAB
1) Erosive Gastroesophageal Reflux Disease
2) Non-Erosive Gastroesophageal Reflux Disease
3) Gastric Ulcer
4) Antibiotic combination therapy for eradication of Helicobacter pylori in patients with peptic ulcers and/or chronic atrophic gastritis.
5) Maintenance therapy after treatment of erosive Gastroesophageal Reflux Disease (For 25mg product only)